Modified Citrus Pectin in a Mouse Model of Colon Cancer Liver Metastasis
An original website-ready summary of a preclinical study published in the World Journal of Gastroenterology.
|
Publication |
Liu HY, et al. World Journal of Gastroenterology. 2008;14(48):7386-7391. |
|
Study type |
Animal study using a mouse model of colon cancer liver metastasis. |
|
Research focus |
The relationship between oral MCP intake, experimental liver metastasis, tumor burden, and galectin-3-related measurements. |
|
Evidence boundary |
Preclinical evidence only. This study does not demonstrate liver-health benefits, cancer prevention, or cancer treatment in humans. |
Research Overview
This study investigated Modified Citrus Pectin (MCP) in a mouse model designed to examine liver metastasis from colon cancer. The researchers focused on galectin-3, a carbohydrate-binding protein associated with cell adhesion and aggregation, and evaluated whether MCP intake was associated with changes in experimental metastatic outcomes.
This publication concerns experimental cancer metastasis to the liver. It is not a study of liver function, liver detoxification, fatty liver disease, or general liver-health support.
Study Design
Seventy-five Balb/c mice were assigned to a negative control, a tumor-model control, or three MCP groups receiving 1.0%, 2.5%, or 5.0% MCP in drinking water. Except for the negative control, mice received CT26 colon cancer cells to establish an experimental liver-metastasis model. MCP administration began on the second day after surgery and continued until assessment on day 21.
Key Research Findings
- Liver-metastasis observations. All mice in the tumor-model control group developed liver metastases. The reported incidence was lower in the 1.0%, 2.5%, and 5.0% MCP groups, at 80%, 73.3%, and 60%, respectively.
- Metastatic lesion count. The high-concentration MCP group showed significantly fewer liver metastatic lesions than the tumor-model control group (P = 0.008).
- Primary tumor burden. The middle- and high-concentration MCP groups had smaller implanted splenic tumor volumes than the tumor-model control group under the conditions of this experiment.
- Galectin-3-related measurements. Tumor-bearing mice had higher serum galectin-3 concentrations than negative controls. MCP did not produce a statistically significant difference in galectin-3 expression within liver metastatic tissue.
Scientific Interpretation
The authors proposed that MCP may interfere with galectin-3-related cell adhesion and aggregation processes rather than directly reducing galectin-3 expression. This mechanism remains a scientific hypothesis based on the experimental evidence available in this mouse model.
These findings are relevant to early research on experimental liver metastasis from colon cancer. They cannot be directly translated into outcomes for people and should not be interpreted as proof that MCP prevents, treats, or cures cancer, or that it improves liver health in humans.
Original Publication
Liu HY, Huang ZL, Yang GH, Lu WQ, Yu NR. Inhibitory Effect of Modified Citrus Pectin on Liver Metastases in a Mouse Colon Cancer Model. World Journal of Gastroenterology. 2008;14(48):7386-7391. DOI: 10.3748/wjg.14.7386.
Request the Full Research Article
Contact us to request the complete publication and discuss Modified Citrus Pectin ingredient specifications and application information.